What are the key considerations for managing patients with uncontrolled…
Asthma is a heterogeneous disease and its management is multifactorial; many patients often…
What is the role of LAMA?
LAMAs and LABAs have complementary mechanisms of action to tackle undertreated bronchoconstriction:1
- LABAs stimulate β2 adrenergic receptors, activating intracellular AC, which then converts AMP into cAMP and ultimately leads to airway smooth muscle relaxation
- LAMAs inhibit activation of M3 receptors, ultimately preventing release of Ca2+ and blocking smooth muscle contraction
Combining ICS/LABA/LAMA therapy provides dual bronchodilation and promotes an anti-inflammatory effect in the airways2–4
Related materials
References
- Bulkhi A et al. Drugs. 2016;76:999–1013.
- Johnson M. Proc Am Thorac Soc. 2005;2(4):320–5.
- Cazzola M, et al. Pulm Pharmacol Ther. 2010;23(4):257–67.
- Jones R, et al. Prim Care Respir J. 2011;20(1):33–45.
Asthma Forward is a registered trade mark of the GSK group of companies.
©2022 GSK group of companies. All rights reserved.
SE-GBL-FVU-WCNT-200060 | December 2022